Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 05, 2024

Tremelimumab Plus Durvalumab for Unresectable Hepatocellular Carcinoma: 4-Year Overall Survival Update

Annals of Oncology


Additional Info

Annals of Oncology
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Ann. Oncol 2024 Feb 19;[EPub Ahead of Print], B Sangro, SL Chan, RK Kelley, G Lau, M Kudo, W Sukeepaisarnjaroen, M Yarchoan, EN De Toni, J Furuse, YK Kang, PR Galle, L Rimassa, A Heurgué, VC Tam, T Van Dao, SC Thungappa, V Breder, Y Ostapenko, M Reig, M Makowsky, MJ Paskow, C Gupta, JF Kurland, A Negro, GK Abou-Alfa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading